IMMUCELL CORPORATION

Basic Information

IMMUCELL CORPORATION
56 EVERGREEN DR
PORTLAND, ME, 04103

Company Profile

n/a

Additional Details

Field Value
DUNS: n/a
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. JENSENIIN P AND NISIN TO TREAT TOPICAL INFECTIONS

    Amount: $191,083.00

    Developing strategies and products to prevent the spread of antibiotic resistance is a national priority. A significant contributing factor in the rise of antibiotic resistance is the use of antibioti ...

    SBIR Phase I 2002 Department of Health and Human Services
  2. A Novel Dry Cow Therapy

    Amount: $70,000.00

    Bovine mastitis is a major economic loss for the dairy industry and indirectly a human hazard because treatment selects for antibiotic resistant bacteria. We propose to develop an novel anti-microbial ...

    SBIR Phase I 2001 Department of Agriculture
  3. Immunomagnetic Separation Assay for Mycobacterium Paratuberculosis

    Amount: $70,000.00

    Johne's disease, caused by Mycobacterium paratuberculosis (M. para), is a chronic inflamatory bowel disease of ruminants. recent literature has fueled an as-yet unresolved debate about whether this or ...

    SBIR Phase I 2001 Department of Agriculture
  4. NOVEL ANTIMICROBIAL TREATMENT FOR MASTITIS

    Amount: $196,247.00

    The development of stategies and products to prevent the spread of antibiotic resistance is a national priority. A significant contributing factor in the rise of antibiotic resistance is the ...

    SBIR Phase I 2001 Department of Health and Human Services
  5. Travelers Diarrhea and E Coli--Prevalence of Pilus AGS

    Amount: $709,721.00

    Enterotoxigenic E. coli (ETEC) is among the most important agents involved in pediatric diarrhea anmost frequently encountered cause of illness in visitors to these regions. It is estimated that 16 mi ...

    SBIR Phase II 1997 Department of Health and Human Services
  6. IMPROVED METHOD OF MONITORING WATER FOR CRYPTOSPORIDIUM

    Amount: $100,000.00

    N/A

    SBIR Phase I 1996 Department of Health and Human Services
  7. Travelers Diarrhea and E Coli--Prevalence of Pilus AGS

    Amount: $100,000.00

    N/A

    SBIR Phase I 1995 Department of Health and Human Services
  8. IDENTIFYING CRYPTOSPORIDIUM PROTECTIVE ANTIGEN GENES

    Amount: $490,365.00

    CRYPTOSPORIDIUM PARVUM IS A SIGNIFICANT HUMAN PATHOGEN WHOSE INCIDENCE HAS INCREASED DRAMATICALLY IN THE LAST DECADE AND THAT CURRENTLY INFECTS APPROXIMATLY 10% OF AIDS PATIENTS INTHE U.S. MORTALITY D ...

    SBIR Phase II 1994 Department of Health and Human Services
  9. STRAIN SPECIFICITY OF ANTI-CRYPTOSPORIDIUM IGG

    Amount: $446,482.00

    CRYPTOSPORIDIUM PARVUM IS A SIGNIFICANT HUMAN PATHOGEN FOR WHICH NO CHEMOTHERAPY HAS BEEN SHOWN TO BE EFFICACIOUS. THE NUMBER OF CASES OF HUMAN CRYPTOSPORIDIOSIS HAS INCREASED DRAMATICALLY IN THE LAST ...

    SBIR Phase II 1994 Department of Health and Human Services
  10. IDENTIFYING CRYPTOSPORIDIUM PROTECTIVE ANTIGEN GENES

    Amount: $49,941.00

    N/A

    SBIR Phase I 1992 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government